<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754452</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A1104-51</org_study_id>
    <nct_id>NCT03754452</nct_id>
  </id_info>
  <brief_title>Evaluation of the Sarcopenia in Hepatobiliary Surgery</brief_title>
  <acronym>SARFO</acronym>
  <official_title>Evaluation of the Prevalence, the Diagnosis Tests, and the Associated Morbimortality of Sarcopenia in Hepatobiliary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The sarcopenia is defined as a loss of muscle mass and a loss of muscle function ( strength
      or performance). Some studies showed that the sarcopenia increase the postoperative
      complications and the overall survival in abdominal surgery. But the sarcopenia is not
      evaluated in the Hepatobiliary surgery. This prospective, monconcentrique study aim to
      evaluate the prevalence of sarcopenia, and its associated morbimortality in hepatobiliary
      surgery for malignant or benign tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the number of patients with a sarcopenia before having a hepatobiliary surgery mesured by impedancemetry and by the muscular force or the speed walking</measure>
    <time_frame>1 month</time_frame>
    <description>for the man : i/impedancemetry BMI&lt;8,87kg/m2 and ii/ a muscular force &lt; 30kg or a walking speed &lt;0,8m/s</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the number of patients with a sarcopenia before having a hepatobiliary surgery mesured by impedancemetry and by the muscular force or the speed walking</measure>
    <time_frame>1 month</time_frame>
    <description>for the woman: i/impedancemetry BMI&lt;6,42kg/m2 and ii/muscular force &lt; 20kg or a walking speed &lt;0,8m/s</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison between the impedancemetry and the abdominopevis CT for the diagnosis of sarcopenia</measure>
    <time_frame>3 months</time_frame>
    <description>impedancemetry used to evaluate the muscular mass
abdominopelvis CT evualate the muscular mass by measuring the muscular area on the L3 section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of the postoperatives complications using the clavien dindo classsification between the patient with sarcopenia and the patient without sarcopenia.</measure>
    <time_frame>4 months</time_frame>
    <description>postoperatives complications evualuated according the clavien dindo classification are : death, nausea, vomit, need of nasogastric tube, liver failure with jaundice, ascites, liver encephalopathy, biliary fistula, biliary peritonitis, hernia, parietal abcess, urinary infection, urinary retention, hematoma, pulmonary embolism, pulmonary infection, pleural effusion, atelectasis, renal failure, hyponatremia, hypernatremia, hypokaliema, hyperkaliema the post operative complication evaluate</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Hepatobiliary Disease</condition>
  <condition>Postoperative Complications</condition>
  <condition>Surgery</condition>
  <eligibility>
    <study_pop>
      <textblock>
        - all patients who should have a hepatobiliary surgery for malignant and benign tumor in
        the universitary hospital center of Angers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hepatobiliary surgery

          -  scheduled surgery

          -  oral consent

        Exclusion Criteria:

          -  pregnancy

          -  patient under low protection

          -  emergency surgery

          -  hepatic encephalopathy stage II, III and IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien BARBIEUX, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien BARBIEUX, Dr</last_name>
    <phone>0241353618</phone>
    <email>Julien.Barbieux@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Barbieux, Dr</last_name>
      <email>julien.barbieux@chu-angers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

